Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Evolving Standard Of Care May Be To Blame For Phase III Failure Of Ulimorelin, Tranzyme Says

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

An evolution in the methods hospitals use to speed gastrointestinal recovery after abdominal surgery may have undercut the Phase III efficacy results for the intravenous ghrelin agonist, which was shown to be no better than placebo in the first of two pivotal trials to report.

You may also be interested in...



Tranzyme Finds Perfect Fit In European Partner For Gastric Motility Drug

Tranzyme and Norgine will co-develop and co-commercialize ulimorelin, which should begin Phase III trials later this year.

FDA’s Strongest REMS To Date: Entereg Approved With Controlled-Distribution

Adolor and marketing partner GlaxoSmithKline's post-operative constipation therapy Entereg is the first drug to clear FDA with its highest level of Risk Evaluation and Mitigation Strategy - a required controlled distribution program. Entereg is at least the fifth new drug, and the second new molecular entity, to be approved with a REMS since the new authority granted by the FDA Amendments Act went into effect March 25

J&J's COVID-19 Vaccine May Face Efficacy Comparison Questions At US FDA Panel Review

Efficacy against moderate to severe/critical COVID-19 was 66%-67%, well above the FDA’s stated 50% efficacy threshold for an EUA but far short of the 94%+ efficacy rates posted by the Pfizer and Moderna vaccines against symptomatic disease; agency says efficacy against specific variants cannot be evaluated at this time because sequencing data are incomplete.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1132098

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel